showed a trendp <0.05
The CMS+fluoxetine group showed a trend of decrease in the plasma level of IL-1β from day 0 to day 120, with significant decrease in IL-1β level on day (60 (206.06±78.41) pg/ml, p <0.05) and day 120 ((141.05±56) pg/ml, p <0.05) as compared to its baseline level on day 0 (344.31±114.33) pg/ml via Wilcoxon signed-rank test.